Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Why This Fast-Growing Dividend Stock Is a Buy


The dip in financial markets has led many investors to flock to stocks that are seen as high-yielding safe havens. This could partly explain why the pharma stock Merck (NYSE: MRK) has rallied 21% year to date while the S&P 500 index has dropped 18% during that time.

And even with the stock's massive gains thus far this year, Merck still looks like a buy. Let's dig into its fundamentals and valuation to learn why.

Last month, Merck reported results for the first quarter, ended March 31. And the company once again topped analysts' estimates.

Continue reading


Source Fool.com

Like: 0
MRK
Teilen

Kommentare